Edelson J, Stroshane R, Benziger D P, Cody R, Benotti J, Hood W B, Chatterjee K, Luczkowec C, Krebs C, Schwartz R
Circulation. 1986 Mar;73(3 Pt 2):III145-52.
The pharmacokinetics of milrinone were studied in sequential ascending doses in New York Heart Association Class III and IV patients receiving oral and intravenous medication. The parameters determined after parenteral administration were estimated by fitting the plasma concentration data to an open two-compartment body model. After oral medication, regression-independent parameters were determined. After either oral or parenteral administration of milrinone, plasma levels were dose dependent and the drug had an apparent first-order terminal elimination half-life of approximately 2 hr. The apparent volume of distribution was approximately 400 to 500 ml/kg, and total body clearance was approximately 130 ml/kg/hr. These values obtained in patients receiving milrinone were compared with those obtained for milrinone in volunteers, as well as those noted with the other inotropic bipyridine, amrinone. Milrinone's elimination from the blood stream patients was slower that that in normal healthy subjects and faster than amrinone's elimination in patients with congestive heart failure. Milrinone's pharmacokinetic parameters in these patients were unchanged after approximately 30 days of continuous oral medication.
在接受口服和静脉用药的纽约心脏协会III级和IV级患者中，以递增剂量序贯研究了米力农的药代动力学。通过将血浆浓度数据拟合到开放二室模型来估计胃肠外给药后测定的参数。口服给药后，确定与回归无关的参数。口服或胃肠外给予米力农后，血浆水平呈剂量依赖性，且该药物的表观一级末端消除半衰期约为2小时。表观分布容积约为400至500 ml/kg，全身清除率约为130 ml/kg/hr。将接受米力农治疗的患者获得的这些值与志愿者中米力农的相应值以及其他强心双吡啶氨力农的相应值进行比较。米力农在患者血流中的消除比正常健康受试者慢，且比充血性心力衰竭患者中氨力农的消除快。在连续口服给药约30天后，这些患者中米力农的药代动力学参数未发生变化。
